Skip to main content
. Author manuscript; available in PMC: 2021 Feb 15.
Published in final edited form as: Clin Cancer Res. 2020 May 21;26(16):4349–4359. doi: 10.1158/1078-0432.CCR-19-3142

Figure 1: AXL targeting overcomes cetuximab resistance.

Figure 1:

A, B: UWSCC PDXs (1 and 64) were implanted into flanks of nude mice and treated with vehicle (oral gavage, methylcellulose, twice daily) and human IgG (intraperitoneal, twice weekly) (UW-SCC1 n=9, UW-SCC64 n=13), cetuximab (intraperitoneal, 0.2 mg/mouse, twice weekly) (UW-SCC1 n=9, UW-SCC64 n=11), R428 (oral gavage, 25mg/kg, twice daily) (UW-SCC1 n=10, UW-SCC64 n=10), or combination of cetuximab with R428 for 28 days (UW-SCC1 n=9, UW-SCC64 n=14). Data was analyzed using linear mixed models where volume was modeled on natural-log scale. **, P<.01 for UW-SCC1 combination compared to single treatments and UW-SCC64 combination compared to cetuximab only.

C, D: Tumors from studies shown in 1A and 1B were stained for Ki67 using IHC. Image quantification shown.